Trial · NCT01876082
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). | PAZOPANIB | 84.8 | 95% Confidence Interval 71.1 to 93.7 | percentage of participants | |
| Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). | Vinblastine and Methotrexate | 45.0 | 95% Confidence Interval 23.1 to 68.5 | percentage of participants | |
| Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1. | PAZOPANIB | Complete response | 0 | 95% Confidence Interval 0 to 0 | percentage of participants |
| Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1. | Vinblastine and Methotrexate | Complete response | 0 | 95% Confidence Interval 0 to 0 | percentage of participants |
| Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1. | PAZOPANIB | Partial response | 41.3 | 95% Confidence Interval 27.0 to 56.8 | percentage of participants |
| Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1. | Vinblastine and Methotrexate | Partial response | 30.0 | 95% Confidence Interval 11.9 to 54.3 | percentage of participants |
| Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1. | PAZOPANIB | Stable disease | 54.4 | 95% Confidence Interval 39.0 to 69.1 | percentage of participants |
| Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1. | Vinblastine and Methotrexate | Stable disease | 45.0 | 95% Confidence Interval 23.1 to 68.5 | percentage of participants |
| Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1. | PAZOPANIB | Progression | 4.4 | 95% Confidence Interval 0.5 to 14.8 | percentage of participants |
| Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1. | Vinblastine and Methotrexate | Progression | 20.0 | 95% Confidence Interval 5.7 to 43.7 | percentage of participants |
| Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1. | PAZOPANIB | Inevaluable for response | 0 | 95% Confidence Interval 0 to 0 | percentage of participants |
| Percentage of Patients Remaining Alive With Best Overall Response as Per RECIST v1.1. | Vinblastine and Methotrexate | Inevaluable for response | 5.0 | 95% Confidence Interval 0.1 to 24.9 | percentage of participants |
| Progression-free Survival | PAZOPANIB | PFS rate at 1 year | 84.8 | 95% Confidence Interval 70.7 to 92.4 | percentage of participants |
| Progression-free Survival | Vinblastine and Methotrexate | PFS rate at 1 year | 68.6 | 95% Confidence Interval 43.0 to 84.5 | percentage of participants |
| Progression-free Survival | PAZOPANIB | PFS rate at 2 years | 65.2 | 95% Confidence Interval 49.6 to 77.0 | percentage of participants |
| Progression-free Survival | Vinblastine and Methotrexate | PFS rate at 2 years | 68.6 | 95% Confidence Interval 43.0 to 84.5 | percentage of participants |
| Overall Survival | PAZOPANIB | OS rate at 1 year | 100.0 | 95% Confidence Interval NA to NA | Percentage of participants |
| Overall Survival | Vinblastine and Methotrexate | OS rate at 1 year | 100.0 | 95% Confidence Interval NA to NA | Percentage of participants |
| Overall Survival | PAZOPANIB | OS rate at 2 years | 97.8 | 95% Confidence Interval 85.6 to 99.7 | Percentage of participants |
| Overall Survival | Vinblastine and Methotrexate | OS rate at 2 years | 100.0 | 95% Confidence Interval NA to NA | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01876082/results